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Abstract
Introduction: The accumulation of neurofibrillary tangles, composed of aggregated hyperphosphorylated tau
protein, starts spreading early in specific regions in the course of Alzheimer’s disease (AD), correlating with the
progression of memory dysfunction. The non-invasive imaging of tau could therefore facilitate the early diagnosis of
AD, differentiate it from other dementing disorders and allow evaluation of tau immunization therapy outcomes. In
this study we characterized the in vitro binding properties of THK5117, a tentative radiotracer for positron emission
tomography (PET) imaging of tau brain deposits.
Results: Saturation and competition binding studies of 3H-THK5117 in post-mortem AD brain tissue showed the
presence of multiple binding sites. THK5117 binding was significantly higher in hippocampal (p < 0.001) and temporal
(p < 0.01) tissue homogenates in AD compared to controls. Autoradiography studies with 3H-THK5117 was performed
on large frozen brain sections from three AD cases who had been followed clinically and earlier undergone in vivo
18F-FDG PET investigations. The three AD cases showed distinct differences in regional THK5117 binding that were
also observed in tau immunohistopathology as well as in clinical presentation. A negative correlation between in vivo
18F-FDG PET and in vitro 3H-THK5117 autoradiography was observed in two of the three AD cases.
Conclusions: This study supports that new tau PET tracers will provide further understanding on the role of tau
pathology in the diversity of the clinical presentation in AD.
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Introduction
Alzheimer’s disease (AD) is the most common form of
dementia among the elderly. The two pathological hall-
marks of AD are fibrillar amyloid beta (Aβ) deposition
in the brain in the form of senile plaques (SPs), and ac-
cumulation of hyperphosphorylated tau protein in the
form of neurofibrillary tangles (NFTs). Although the
relationship between SPs and NFTs remains unclear,
both appear to precede the onset of clinical symptoms
of AD [1]. Several biomarkers have been developed to
target the pathological features in vivo in order to help
the clinical diagnosis of AD, showing increased reliability
with time. Quantification of Aβ and tau from cerebro-
spinal fluid (CSF) appears consistent with quantification of
the lesions [2, 3]. However this invasive method is indirect,
as the relationship between CSF biomarkers and AD le-
sions is still unclear [4]. Positron emission tomography
(PET) imaging has been developed over recent decades
and is now a very important tool for diagnosing AD,
with particular regard to in vivo assessment of the cere-
bral amyloid load. However, the pathophysiological link
between formation of the amyloid plaques and neuro-
degeneration is still unknown, and amyloid-targeting
drug therapies have so far failed to show conclusive
results.
In order to visualize and increase our understanding of
the time course of NFT deposition during the develop-
ment of AD and other dementia disorders, there is cur-
rently an attempt to develop PET tracers that are specific
for tau protein [5]. Postmortem studies on patients with
confirmed AD have shown a correlation between NFTs
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(but not SPs) and cognitive impairment [6–8]. Since tau
aggregates are mainly intracellular, the radiotracer has to
cross the blood–brain barrier as well as the cell mem-
brane. Moreover, the tau ligand needs to be very specific
for NFTs; in some regions of AD affected brains, amyloid
plaques and NFTs occur together, although the occurrence
of amyloid plaques is 5–20 times greater than that of
NFTs [9]. The PET tracer 18F-FDDNP, initially introduced
as an Aβ PET tracer, also binds to NFTs [10]. A negative
correlation between 18F-FDDNP binding and episodic
memory has been reported in patients with AD and pa-
tients with mild cognitive impairment (MCI) [11], but this
tracer showed limitations with low levels of specific bind-
ing [12]. Recently, several PET tau tracer candidates from
three different chemical classes have been developed, in-
cluding the THK analogues 18F-THK523, 18F-THK5105,
and 18F-THK5117, as well as the ligands 11C-PBB3,
18F-T808 and 18F-T807 [5, 13]. Clinical studies with
18F-THK5117, 11C-PBB3, and 18F-T807 are currently
in progress [14–17].
In this study, we characterized the in vitro binding
properties of THK5117 in large frozen sections from
autopsied AD brains, and compared its binding pattern
with measured tau histopathology as well as with previ-
ous in vivo measurement of 18F-FDG and 11C-Pittsburgh
compound B (PIB) PET imaging in the same patients.
In this study, we focused on the 18F-THK5117 tracer
that was reported to have good binding properties in AD
tissue [17]. Here we aimed at investigating in greater de-
tails the THK5117 binding using large frozen sections
from autopsied AD brains, and compared its binding
pattern with measured tau histopathology as well as with
previous in vivo measurement of 18F-FDG PET imaging
in the same patients.
Materials and methods
Chemicals
1-Fluoro-3-((2-(4-([3H]methylamino)phenyl)quinolin-6-
yl)oxy)propan-2-ol (3H-THK5117; specific activity, SA
2.2 GBq/μmol) and N-methyl-[3H]2-(4′-methylamino-
phenyl)-6 hydroxybenzothiazole (Pittsburgh compound
B, 3H-PIB; SA 2.3 GBq/μmol) were custom synthesized by
Quotient Bioresearch (Cardiff, UK). Unlabeled THK5117
was synthesized by Tanabe R&D Service (Osaka, Japan)
and by Quotient Bioresearch (Cardiff, UK). 2-(1-{6-
[(2-fluoroethyl) (methyl)amino]-2-naphthyl}ethylidene)-
malononitrile (FDDNP) was a kind gift from Dr Jorge
R. Barrio (UCLA, USA). BTA-1 2-(4-methylaminophe-
nyl)benzothiazole was purchased from Sigma Aldrich
(Sweden).
In vitro binding assays
Human brain tissues from eight Alzheimer patients and
eight controls were obtained from the Netherlands Brain
Bank (demographic details in Table 1), and homogenized
in PBS containing 0.1 % BSA and protease/phosphatase
inhibitor.
Optimal conditions for the binding assay study were
determined in preliminary experiments by varying the
time of incubation (1 h, 2 h or 3 h), the tissue concen-
tration (100 μg/mL, 200 μg/mL, 500 μg/mL or 750 μg/
mL) and the buffer (PBS, PBS + 0.1%BSA or Tris buffer).
Saturation binding assays were carried out with incu-
bation of temporal cortex and hippocampus homoge-
nates (0.1 mg tissue) with 3H-THK5117 (0.04-270 nM)
for 2 h at room temperature. Non-specific binding was
determined with 1 μM THK5117. The binding reaction
was terminated by filtering through glass fiber filters
(pre-soaked for 3 h in 0.3 % polyethylenimine), and rins-
ing three times with cold binding buffer, and counted
with a beta scintillation counter (Beckman Coulter
LS6500). The results were analyzed with GraphPad
Prism software (version 5.0f for Mac OS X, GraphPad
Software, San Diego California USA). The equilibrium
dissociation constant (Kd) and maximum number of
binding sites (Bmax) were then determined.
Table 1 Clinical information for binding assay studies
Age
(Years)
Gender
(M/F)
ApoE
(E/E)
Braak
stage
Postmortem
delay (hours)
Alzheimer
cases
59 F 4/4 5 4
61 M 3/3 5 4
66 F 4/3 5 7
70 M 4/4 4 4
75 F 4/4 5 6
78 M 4/4 5 7
81 F 4/3 5 6
85 F 3/3 4 6
72 ± 9 3 M/5 F 2 E3 4-5 5 ± 1
6 E4
Controls 50 F 3/3 1 17
62 M 3/3 1 7
71 F 3/2 1 7
77 F 3/3 1 3
78 M 3/3 1 7
79 M 3/3 2 9
81 M 3/3 2 8
84 F 3/3 1 4
73 ± 11 4 M/4 F 8 E3 1-2 8 ± 4
0 E4
The table presents information for the binding studies cases from which
homogenates have been extracted. The age at death, gender, apolipoprotein
E (ApoE) genotype, Braak stage at cerebral pathological assessment, and
post-mortem delay are given for each patient included in the study
M =male; F = Female. Temporal lobes from AD cases mentioned in bold have
been used for the saturation and competition studies, as well as the
hippocampus from the 75 years-old AD case
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The specificity and selectivity of 3H-THK5117 binding
was determined by incubating homogenates (0.1 mg tis-
sue) from Alzheimer’s patients’ temporal cortex and
hippocampus with 3H-THK5117 (3 nM), in the presence
of THK5117 (10−5 -10−13 M), FDDNP (10−6 -10−14 M) or
BTA-1 (10−5 -10−13 M). The results were analyzed with
GraphPad Prism software, and the resulting inhibitory
constants (Ki) were determined.
Regional binding studies with 3H-THK5117 were carried
out on the brain homogenates from temporal cortex,
frontal lobe, parietal lobe, caudate nucleus, hippocampus
and cerebellum that were incubated with a single concen-
tration of 3H-THK5117 (3 nM). Non-specific binding was
determined with 1 μM of THK5117. Comparisons be-
tween AD and control tissues were made using Mann–
Whitney non-parametrical tests, with a threshold for
significance of p < 0.05.
Autoradiography binding studies in Alzheimer’s disease
and control autopsy brain tissue
Postmortem brain tissue for autoradiography studies was
obtained from three patients with AD that all three had
been clinically followed (by A.N.) at the Department of
Geriatric Medicine, Karolinska University Hospital,
Huddinge, Sweden. The left hemisphere of each brain was
frozen in large block sections. The right hemispheres were
fixed in formaldehyde, brain tissue was sampled according
to the BrainNet Europe protocol and histopathological
investigations were undertaken (by I.N.) to confirm AD
pathology (see Additional file 1).
AD case one was referred for memory assessment at
49 years of age due to complaint of progressive memory
impairment over 2 years. The patient was diagnosed with
AD, and received galantamine (cholinesterase inhibitor)
and memantine (NMDA antagonist) treatment. The pa-
tient was followed clinically and underwent two 18F-FDG
PET at MMSE 18/30 and 12/30, respectively. After 4 years
in a nursing home, the patient died at the age of 60, and
autopsy (post-mortem delay of 25 h) confirmed AD path-
ology, with Braak stages V-VI. General atrophy of the gyri
was observed, especially the frontal lobe, and severe atrophy
of the amygdala and the anterior part of the hippocampus.
AD case two was referred at the age of 71 with a 7-
year history of memory complaint. Neuropsycho-
logical testing showed impairment in several cognitive
domains with a MMSE score of 26/30, and CSF bio-
markers were pathological. The patient was diagnosed
with AD, treated with phenserine and rivastigmine
(cholinesterase inhibitors) and underwent 18F-FDG
PET. The patient died aged 79 years, after being in a nurs-
ing home for 2 years, and autopsy (post-mortem delay of
16 h) confirmed AD with at least Braak stage V. The brain
presented with generally slightly smaller gyri than nor-
mal, and atrophic anterior part of the hippocampus.
AD case three was referred at 70 years of age with a 7-
year history of memory complaint. Neuropsychological
testing showed disturbances in episodic memory, spatial
orientation, attention, and MMSE was at 26/30. CSF bio-
markers were pathological, and MRI showed frontal atro-
phy. The patient was diagnosed with AD, treated with
rivastigmine (anticholinesterase inhibitor) and memantine
(NMDA antagonist, and underwent three 18F-FDG PET
examinations at 70, 72 and 75 years of age. The patient
died aged 81 years after four years in a nursing home, and
autopsy (post-mortem delay of 17 h) confirmed Braak
stages V-VI with slight atrophy of the frontal lobe.
Fig. 1 Saturation binding curve (a) and Scatchard plot (b) for 3H-THK5117 (0.04-270 nM) in temporal lobe brain homogenates from four patients
with AD. The solid regression line was determined by GraphPad Prism software and corresponds to the low affinity site. The dotted regression
line was determined manually and corresponds to the high affinity site. The corresponding Kd and Bmax values are given below the curve.
(c) Competition binding curve between THK5117 (10−13-10−5 M) and 3H-THK5117 (3 nM) in temporal lobe brain homogenates from four
patients with AD. Analyses from non-linear regression using a least square ordinary fit in GraphPad Prism software showed three binding
sites. Ki: inhibitory constant. r2 = regression coefficient
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Control case was a 76-year-old female, with a postmor-
tem delay of 4 h and Braak stage I, obtained from the
Neuropathology of Dementia Laboratory (Indiana Univer-
sity School of Medicine, Indianapolis, USA).
Frozen brain sections (80 μM) from the left hemispheres
of the three AD cases and the healthy control case were
cut with a cryostat at −20 °C and thaw-mounted on
chrome alum gelatin-subbed slides following a previously
described protocol [18].
For each case, frozen sections were dried, pre-
incubated for 10 min with PBS + 0.1%BSA, and were
then incubated for one hour with 4 nM 3H-THK5117.
The non-specific binding assay was performed on adja-
cent sections in the presence of 10 μM THK5117. After
incubation, sections were washed 3 times for 5 min with
cold incubation buffer, dipped into cold distilled water,
and allowed to dry for at least 24 h. A Fujifilm BAS-
2500 phosphor imaging plate was then exposed to the
section, along with a tritium standard, for three days
(Larodan Fine Chemical AB, Malmö, Sweden) before be-
ing scanned by a phosphoimager Fujifilm BAS-2500.
Binding of the tracer was quantitatively assessed using
MultiGauge Fujifilm software (V3.0). Two independent
raters manually segmented different regions of interest,
as defined by Duvernoy in “The Human Hippocampus”
[19], resulting in regional mean uptake values for each
segment. Inter-rater agreement was assessed for all uptake
values using a Bland-Altman plot, with limits of agree-
ment set to 95 %. When agreement was satisfactory, re-
gional uptake values from both raters were averaged for
subsequent analyses.
Autoradiography with enantiomerically pure (S)-18F-
THK5117 was also performed on adjacent sections for
each case. The sections were pre-incubated for 10 min
Fig. 2 Regional binding distribution of 3H-THK5117 in homogenates from eight patients with AD and eight healthy controls. EOAD = patients
with Early onset Alzheimer’s Disease, LOAD = patients with Late Onset Alzheimer’s Disease, Front. =Frontal, Pariet. = Parietal, Hippo = Hippocampus,
Temp. = Temporal. Statistical significance is shown for group comparison between patients (EOAD + LOAD) and controls. ** p < 0.01; ***p < 0.001
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with PBS + 0.1%BSA and incubated for 15 min with
0.5 MBq/mL (S)-18F-THK5117. Non-specific binding
was determined in adjacent sections by adding 10 μM
THK5117. After incubation, sections were washed three
times 5 min with cold buffer and then dipped into
50 % v/v cold distilled water and ethanol before drying
in an incubator at 37 °C. A phosphor imaging plate was
exposed to the sections overnight, before scanning with
a phosphoimager (Cyclone plus, Perkin Elmer).
Autoradiography and immunostaining on small paraffin
AD brain sections
Routine pathology with AT8 has been performed on anter-
ior and posterior hippocampus paraffin sections from the
right hemisphere of the three AD cases. Autoradiographies
with 3H-THK5117 on adjacent sections have been per-
formed after deparafinization following the same protocol
as cited above.
A paraffin section from hippocampus of a patient with
confirmed AD (70 years old at death, Braak VI, from the
Netherlands brain bank) were quenched and stained with
THK5117 following the procedure used by Okamura and
colleagues [17, 20] for autofluorescence studies. An adja-
cent section was labeled with AT8 anti-tau and assessed
using the EnVision + System HRP (DAB) (Dako Denmark)
detection method.
In vivo imaging
Image Acquisition: PET Data: All 18F-FDG PET investiga-
tions were carried out at the Uppsala PET centre using
ECAT EXACT HR+ scanners (Siemens/CTI). The mean
injected dose was 229 ± 49 MBq. Acquisition was per-
formed during 45 min after injection. All reconstructed
frames were realigned to correct for patient motion during
each PET scan. The sum image from 25 to 45 min was
used for analyses.
Fig. 3 Autoradiography results from adjacent left frozen hemisphere sections from AD case one and the control case. (a) 3H-THK5117 in AD case
one. (b) 3H-THK5117 + 10−5 M of THK5117 in AD case one. (c) 3H-THK5117 in control case. (d) 3H-THK5117 + 10−5 M of THK5117 in control case
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MRI Data: Case two and case three underwent a struc-
tural T1 MRI sequence using a 3 T Siemens Trio scanner.
Images were acquired with a slice thickness of 1.5 mm and
were reconstructed to 1.0 x 1.0 x 1.0 mm isometric voxels.
Regional quantification of 18F-FDG PET images for
correlation with in vitro autoradiography: In order to
compare the in vitro quantitative autoradiography binding
measurements with the in vivo 18F-FDG PET images, the
coronal section of the T1 MRI judged to correspond best
to the relevant autoradiography section was manually
segmented by two independent raters. The atlas used
for segmentation of autoradiographies (see above [19])
was used to define regions of interest on the T1 section.
Mean uptake values were calculated for each of these
regions on the registered 18F-FDG PET images.
Inter-rater agreement was assessed for all resulting re-
gional uptake values using a Bland-Altman plot, with
limits of agreement set to 95 %. When agreement was
satisfactory, regional uptake values from both raters
were averaged for subsequent analyses.
The relationship between 18F-FDG regional uptake values
measured by PETand the in vitro binding results from auto-
radiography was assessed using a Spearman correlation test.
Results
THK5117 multiple binding sites
Saturation binding assay performed with increasing con-
centrations of 3H-THK5117 (0.04-270 nM) in post-mortem
AD temporal brain tissue homogenates showed saturation
with a Bmax of 1416 fmol/mg and Kd2 of 24nM (Fig. 1a).
A second binding site (Bmax 250fmol/mg and Kd1 of 2.2
nM) was determined manually from the Scatchard plot
(Fig. 1b). Saturation binding data from the temporal cortex
were averaged from all seven experiments.
Saturation binding in the hippocampus (one Alzheimer
brain) revealed two binding sites, with Kd values of 3.1
nM and 34 nM and Bmax values of 250 fmol/mg and
1226 fmol/mg, respectively (Additional file 2).
Competition studies with increasing concentration of un-
labeled THK5117 (10−5-10−13 M) and 3H-THK5117 (3 nM)
in AD temporal cortices (Fig. 1c) showed two binding sites
(Ki2 = 16 nM, Ki3 = 750 nM). Results were averaged from
ten competition experiments. Setting the constraints in the
statistical model to >100 for the start of the curve indicated
the presence of a potential third site (Ki1 = 1 pM).
Selectivity of THK5117
Increasing concentrations of FDDNP showed a trend for
competition with 3H-THK5117 for a super-high affin-
ity binding site (picomolar range) and a low affinity
site (micromolar range; Additional file 3a). No compe-
tition was observed neither between 3H-THK5117 and
BTA-1 nor between 3H-PIB and unlabeled THK5117
(Additional file 3b).
Regional binding distribution of 3H-THK5117 in tissue
homogenates
The regional binding distribution of 3H-THK5117 in the
AD cases was highest in the hippocampus (198 ± 67
fmol/mg), followed by the caudate nucleus (198 ± 30
fmol/mg), the temporal lobe (110 ± 47 fmol/mg) and the
parietal lobe (105 ± 46 fmol/mg), and was very low in
the cerebellum (Fig. 2). Statistical group comparisons re-
vealed a significantly higher binding in the AD than in
the controls in the hippocampus (p < 0.001) and the
temporal region (p = 0.005) (Fig. 2).
Binding in caudate nucleus was found higher in the
three patients with early onset AD (EOAD<65 years old)
cases than in the three with late onset AD (LOAD>65
years old).
Table 2 Clinical information and regional specific binding of
3H-THK5117 on autoradiography sections from the three
Alzheimer cases
Demographic data
Demography AD Case 1 AD Case 2 AD Case 3
Onset EOAD LOAD LOAD
Gender (M/F) F F M
ApoE alleles (E/E) 4/4 4/4 4/4
MMSE at time of last PET 12 26 25
Age at death (years) 60 79 81
Time between last PET
and death (years)
7 7 5
3H-THK5117 specific binding in regions of interest (fmol/mg)
Regions of interest AD Case 1 AD Case 2 AD Case 3
Hippocampus 693 171 112
Entorhinal cortex 713 126 53
Fusiform gyrus 585 189 52
Inferior temporal gyrus 764 125 59
Middle temporal gyrus 495 140 48
Superior temporal gyrus 363 114 53
Insular cortex 423 68 50
Postcentral gyrus 312 77 75
Precentral gyrus 310 32 102
Middle frontal gyrus 276 55 56
Superior frontal gyrus 344 57 114
Cingulate gyrus 292 120 110
Putamen 242 NA NA
Thalamus 349 NA NA
Amygdala 507 NA NA
3H-THK5117 binding values were obtained by subtracting the nonspecific
binding values from the total binding values. Regions of interest were defined
for each case by manual segmentation of the section
AD = Alzheimer’s Disease; EOAD = Early Onset Alzheimer’s Disease; LOAD = Late
Onset Alzheimer’s Disease; M =male; F = Female; NA = not available
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Regional distribution of 3H-THK5117 evaluated by
autoradiography
The total and non-specific binding autoradiograms for AD
case one and the control case are shown in Fig. 3, while
autoradiograms for AD case two and three are shown in
Additional file 4. From those autoradiograms, fourteen re-
gions of interest could be defined for case one, and twelve
for case two and three. Quantitative results are presented
in Table 2 for each case.
Inter-rater agreement for manual segmentation was
within the 95 % limit for agreement.
Specific 3H-THK5117 binding in case one was intense
in the hippocampus, the temporal cortex and the frontal
cortex. 3H-THK5117 binding in AD case two and three
was less intense than in AD case one; specific binding was
high in the hippocampus and the cingulate for AD case
two, and high in the hippocampus and the frontal cortex
for AD case three. Furthermore, the binding intensities
differed within a single brain region, as illustrated by the
values in temporal gyri for case one. Low and regional
binding was found in the control case compared to the
three AD cases (Fig. 3).
As shown in Table 2, there were large differences
among the three patients with respect to 3H-THK5117
binding in the regions studied. Regional 3H-THK5117
binding was highest in case one and lowest in case three.
The differences between the three cases were greatest
in the entorhinal cortex, inferior temporal cortex, mid-
dle temporal cortex and fusiform gyrus. In all three
cases, hippocampus was one of the regions with highest
3H-THK5117 binding.
Autoradiography results for (S)- 18F-THK5117 indi-
cated a similar binding pattern to that for 3H-THK5117
(Additional file 5).
Validation of the selectivity of THK5117 towards TAU
Autoradiography with 3H-THK5117 and immunostain-
ing with AT8 performed on adjacent sections of anterior
and posterior part of hippocampus of AD case one
showed identical binding pattern (Fig. 4).
Autofluorescence performed on the hippocampus section
from another AD case revealed THK5117 binding on the
neurofibrillary tangles confirmed by tau immunostaining
with the AT8 tau antibody on the adjacent section (Fig. 5).
Correlation of in vivo 18F-FDG PET with in vitro 3H-THK5117
autoradiography binding results
Regional in vivo 18F-FDG PET data were available for all
three AD cases. A hypometabolism pattern characteristic
of AD was observed in all cases. The inter-rater agreement
for manual segmentation was within the 95 % limit of
agreement for all defined regions of interest in all patients.
Fig. 4 Comparison between AT8 staining (a-b) and 3H-THK5117 autoradiography (c-f) performed on paraffin sections from anterior and posterior
hippocampus of AD case one’s right hemisphere. (c-d) 3H-THK5117 autoradiography, (e-f) 3H-THK5117 + 10−5 M of THK5117 autoradiography for
anterior and posterior hippocampus respectively
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For the three cases, hippocampus showed the lowest
18F-FDG PET uptake and one of the highest 3H-THK5117
binding results (see Additional file 6 for 18F-FDG uptake
values).
A significant negative correlation was found in AD case
one and two between in vivo uptake of 18F-FDG and in
vitro 3H-THK5117 autoradiography binding while no sig-
nificant correlation was observed for AD case three
(Fig. 6).
Discussion
In this study we explored the binding properties and re-
gional distribution of the novel PET tau tracer THK5117
in autopsy brain tissue homogenates and autoradiography
on whole frozen brain hemisphere. 3H-THK5117 showed
a high affinity for tau, as observed in competition binding
studies where 3H-THK5117 demonstrated up to three
binding sites. In saturation binding assays, we could ob-
serve two binding sites, one being in the nanomolar range,
in agreement with Okamura et al. [17].
Binding assays performed in brain homogenates should
reflect the actual binding situation more accurately and
are supposed to be more reliable than binding assays per-
formed on tau fibrils, but they also reflect pathological
variability between subjects, possibly leading to more het-
erogeneity in the results.
Since the selectivity of a PET tracer for its target is of
crucial importance, THK5117 binding was assessed in
competition studies with other compounds. No competi-
tion was observed with the amyloid tracers 3H-PIB and
BTA-1. More interestingly, a trend for competition was
observed between 3H-THK5117 and FDDNP at the super-
high affinity binding site. FDDNP was initially introduced
as Aß PET tracer [12, 21] but has then been reported to
also bind to NFTs [22, 23], and to correlate with cognitive
decline [11]. As suggested previously [24], the THK com-
pounds family (such as THK523 and now THK5117)
could share some binding properties with FDDNP; all of
them are of interest for targeting tau pathology.
The 3H-THK5117 binding in AD tissue homogenates
was highest in both the hippocampus and temporal cortex
which are regions that are expected to be more severely
affected earlier by tau pathology in AD [6, 25]. Consistent
findings were also observed in brain hemisphere sections
used in autoradiography, with the highest binding in
the temporal regions for the three AD cases. Interest-
ingly, those three cases, all with different clinical pre-
sentations, differed markedly in regional 3H-THK5117
binding intensity.
In AD case one, presenting with an early onset of AD,
3H-THK5117 binding in the hippocampus and the ento-
rhinal cortex was about six times higher than in the
other two AD cases. This difference could also been ob-
served on AT8 staining for tau, in particular in hippo-
campus. Indeed case one’s brain was severely affected by
the disease, in particular in those temporal regions, and
was very shrunken, due to neuronal loss. This atrophy
could partly explain the higher extent of binding com-
pared to case two and three, in whom the superficial
layers were more compact and dense. One could also as-
sume that the high level of 3H-THK5117 binding could
be related to the early onset of the disease. It has been
suggested that EOAD and LOAD might have different
mechanisms for disease progression [26]. Some of the
AD patients included in the binding assays also had
EOAD. However, there were no differences between
EOAD and LOAD in 3H-THK5117 binding except in
the caudate nucleus homogenates, where it was higher
in EOAD tissue than in LOAD tissue. Although tau
pathology has been reported in the striatum of both
EOAD and LOAD brains [27], no comparisons between
the two clinical entities in this respect have been re-
ported to our knowledge. Interestingly, control tissue
also showed binding in caudate, that appeared similar to
the one observed in LOAD tissue. In recent in vivo Tau
PET imaging studies, high signal has been reported in
Fig. 5 Autofluorescence of THK5117 and AT8 immunostaining on
Alzheimer’s disease brain sections. (a) Autofluorescence results for
THK5117 on paraffin Alzheimer’s disease brain section (bar = 16 μM),
(b) Immunostaining with AT8 tau antibody on the adjacent section
(scale bar = 12 μM)
Lemoine et al. Acta Neuropathologica Communications  (2015) 3:40 Page 8 of 11
striatum of both controls and AD patients. Although it
has been suggested that this binding would be non-
specific, no evidence has been provided yet. Both our
binding assays and autoradiography in AD case one
showed to some extent specific binding in striatum of
both control and AD cases. Our limited sample prevents
Fig. 6 Correlations between in vitro 3H-THK5117 autoradiography binding and in vivo 18F-FDG uptake in case one (a), case two (b), and case three (c).
All 18F-FDG uptake values are reported as standard uptake value ratios (SUVR) with reference to the grey matter of the cerebellum. Temporal regions
are shown in blue, frontal regions in orange, the rest in grey. r and p values from the Spearman test are reported for significant correlations
(significance threshold: p < 0.05). Regions were defined by manual segmentation. hippo = hippocampus; inf = inferior; mid =middle; sup = superior
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us from drawing any conclusion, and specific investiga-
tion addressing this issue should be performed.
Compared to case one and three, case two showed an
in-between binding of 3H-THK5117 in hippocampus and
frontal cortex, which is in agreement with the numerous
tau lesions reported on pathological examination. 3H-
THK5117 binding was lowest in case three, who had only
few tangles in the frontal cortex despite a lot of tau in the
granular cell layer of the hippocampus. This interesting
pattern is in agreement with the clinical presentation of
the patient, who showed dramatically pronounced epi-
sodic memory impairment, but was less impaired in global
cognition than the other two patients. One limitation of
this study is the sample size. The in vitro investigations
need to be performed on a larger sample to address the
variability of both clinical and pathological presentation in
AD patients. Furthermore, a next step would be to investi-
gate THK5117 binding distributions in other tauopathies.
Since tau exists in different forms, it would be important
to assess the form of tau to which THK5117 is binding, as
this may have implications for our understanding of the
different tauopathies.
Autoradiography binding studies with (S)-18F-THK5117
indicated binding patterns that were very similar to those of
3H-THK5117 in all three patients, although autoradiography
with tritiated compounds is associated with higher resolution
than autoradiography with fluorinated compounds. This
finding is very promising for use in in vivo PET scans.
One interesting characteristics of this study was that
autoradiography was performed on hemisphere sections
from three patients with confirmed AD who had previously
undergone 18F-FDG during the early course of their disease.
Thus, it was possible to compare the post-mortem
THK5117 binding patterns with the ante-mortem patterns
for 18F-FDG in the same subjects. Although these findings
should be viewed with caution, since the PET scans had
been performed several years before death, a negative
correlation between in vivo 18F-FDG uptake and post-
mortem THK5117 binding was observed in two AD cases.
More severe tau pathology is observed in regions with
lower cerebral glucose metabolism while less tau pathology
is found in regions with preserved metabolism, which may
support the assumption that NFTs trigger neuronal dys-
function. No significant correlation was found for case
three. Since α-synucleinopathy was reported in this case, al-
though little is known about the relationship between α-
synuclein and tau in AD, pathological processes involving
α-synuclein may have influenced pathological progression
in this patient.
Conclusions
In conclusion, the tau tracer THK5117 binds with high
affinity and good selectivity to cerebral tau lesions. The
binding patterns for 3H-THK5117 not only showed
significant differences between AD patients and controls,
but also appeared to reflect the different tau pathology
as well as clinical symptoms of the patients. The use of
different in vivo tau tracers in PET imaging will shed
further light on the role of tau pathology in the time
course of AD and its concurrent clinical features.
Additional files
Additional file 1: Immunostaining of AD case one, two and three
using AT8 and Clone 6 F/3D staining in Frontal cortex (A-F) and
Hippocampus (G-L). J’,K’,L’ show a zoom in the granular cell layer of
the dentate gyrus. All images are magnification 4x, scale bar = 300 μM
except for J’, K’and L’ magnification 20x scale bar = 100 μM. AD case one:
Numerous NFTs were seen throughout the cortex in AT8 staining
prominently in superficial layers (D). Tangles were also found in many of
the remaining hippocampal nerve cells, and intracytoplasmic positivity
was seen in several granular cells of the dentate gyrus (J, J’). Staining
with clone 6F/3D showed large numbers of Ab plaques in the cortex,
many with a central core (A), while fewer were found in the
hippocampus (G).AD case two: AT8 staining indicated numerous NFTs in
the frontal cortex (E). In the granular cells, only a few neurons stained
positively for tau (K, K’). Numerous Ab plaques were seen in the cortex
(B), some of which had a core, while there were only a few plaques in
the hippocampus (H). Staining of vessels in the cortex and
leptomeninges was extensive.AD case three: AT8 positivity was found in
relatively few cortical neurons prominently in superficial layers as for case
one (F), and a peculiar pattern was seen in the granular cell layer of the
dentate gyrus with prominent intracytoplasmic staining (L, L’). Staining
with clone 6F/3D revealed extensive amyloid in the cortical vessels, but
very few cortical plaques (C).
Additional file 2: A. Saturation binding curve and B. Scatchard plot
of 3H-THK5117 (0.04-270nM) for hippocampus homogenates of one
AD patient. The plain regression line was determined by GraphPad
Prism software and corresponds to the low affinity site. The dotted
regression line was determined manually and corresponds to the high
affinity site. Corresponding Kd and Bmax values are mentioned below
the curve. C. Competition binding curve between THK5117 (10-13-10-5 M)
and 3H-THK5117 (3nM) for hippocampus homogenates of one AD case
(75 years old). Analyses from non-linear regression using a least square
ordinary fit in GraphPad Prism software show two different binding sites.
Ki Sup Hi = Ki for super high binding site; Ki Hi = Ki for high binding site;
Ki Lo = Ki for low binding site.
Additional file 3: Competition binding curve for temporal cortex
homogenates of four AD cases between 3H-THK5117 (3nM) and A.
unlabeled FDDNP (10-6-10-14 M); B. unlabeled BTA-1 (10-5-10-13 M).
Analyses from non-linear regression using a least square ordinary fit in
GraphPad Prism software show no common binding site. Ki: inhibitory
constant. r2 = regression coefficient. "Ambiguous" is a term coined by
GraphPad to describe a fit that doesn't really nail down the values of all
the parameters (extract from GraphPad Curve Fitting Guide).
Additional file 4: Autoradiography in AD case two and AD case
three. A-B Autoradiography of adjacent left hemisphere sections
from case two. A. Autoradiography with 3H-THK5117. B. Autoradiography
with 3H-THK5117 + 10-5 M of THK5117. C-D Autoradiography of adjacent
left hemisphere sections from case three. C. Autoradiography with
3H-THK5117. D. Autoradiography with 3H-THK5117 + 10-5 M of THK5117.
Additional file 5: Autoradiography results from adjacent left
hemisphere sections from the three AD cases with (S)-18F-THK5117.
Additional file 6: Regional standard uptake values for 18F-FDG PET
scans in threeAD cases. Regions of interest were defined for each case
by manual segmentation of a coronal section of the individual’s MR
image (case two & three) or an MR template (case one). Segmentations
were performed on the left hemisphere in order to match the
autoradiography results. Values are expressed as Standard uptake values
with cerebellum uptake as reference (SUVR). NA = not available.
Lemoine et al. Acta Neuropathologica Communications  (2015) 3:40 Page 10 of 11
Competing interest
Dr Nobuyuki Okamura has received financial support from GE Healthcare, UK
for TAU PET tracer development.
Dr Per-Göran Gillberg is an employee of Albire AB, Göteborg, Sweden
Acknowledgments
The authors would like to thank Björn Brunström and Margareta Mattsson
from the Evolutionary Biology Centre and Sergio Estrada from the
Department of Medicinal Chemistry, Preclinical PET Platform in Uppsala
University, for professional help. The authors would like to thank Dr Jorge
Barrio for the kind gift of FDDNP.
This study was financially supported by the Swedish Research Council
(project 05817), Swedish Brain Power, the Regional Agreement on Medical
Training and Clinical Research (ALF) for Stockholm County Council, the
Strategic Research Programme in Neuroscience at Karolinska Institutet, the
Foundation for Old Servants, Gun and Bertil Stohnes Foundation, KI
Foundations, the Swedish Brain Foundation, the Swedish Alzheimer’s
Foundation (Alzheimerfonden), Demensfonden, the Wenner-Gren Foundation,
Foundation of Sigurd and Elsa Golje's memory, the EU FW7 large-scale integrat-
ing project INMiND (http://www.uni-muenster.de/INMiND), Swedish Foun-
dation for Strategic Research (SSF), and US Grant P30 AG010133.
Author details
1Department of Neurobiology, Care Sciences and Society, Center for
Alzheimer Research, Division of Translational Alzheimer Neurobiology,
Karolinska Institutet, Novum, 5th floor, Stockholm S-14157, Sweden.
2Preclinical PET Platform, Department of Medicinal Chemistry, Faculty of
Pharmacy, Uppsala University, Uppsala, Sweden. 3PET Centre, Centre for
Medical Imaging, Uppsala University Hospital, Uppsala, Sweden. 4Department
of Pathology & Laboratory Medicine, Indiana University School of Medicine,
Indianapolis, IN, USA. 5Department of Pharmacology, Tohoku University
School of Medicine, Sendai, Japan. 6Department of Pathology, Karolinska
University Hospital, Stockholm, Sweden. 7Department of Geriatric Medicine,
Karolinska University Hospital Huddinge, Stockholm, Sweden.
Received: 14 June 2015 Accepted: 15 June 2015
References
1. Nordberg A (2010) Amyloid imaging in early detection of Alzheimer’s
disease. Neurodegener Dis 7:136–138. doi:10.1159/000289223
2. Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H,
Pyykko OT, Helisalmi S, Alafuzoff I, Hiltunen M et al (2012) CSF biomarkers
for Alzheimer disease correlate with cortical brain biopsy findings.
Neurology 78:1568–1575. doi:10.1212/WNL.0b013e3182563bd0
3. Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels
correlate with amyloid-neuropathology in a population-based autopsy
study. Neurology 60:652–656
4. Zetterberg H, Lautner R, Skillback T, Rosen C, Shahim P, Mattsson N,
Blennow K (2014) CSF in Alzheimer’s disease. Adv Clin Chem 65:143–172
5. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (2015) Tau imaging:
early progress and future directions. The Lancet Neurology 14:114–124.
doi:10.1016/S1474-4422(14)70252-2
6. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary
tangles but not senile plaques parallel duration and severity of Alzheimer’s
disease. Neurology 42:631–639
7. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP (1995)
Neocortical neurofibrillary tangles correlate with dementia severity in
Alzheimer’s disease. Arch Neurol 52:81–88
8. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison
JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load,
predict cognitive status in Alzheimer’s disease. Neurology 60:1495–1500
9. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P,
Buxbaum JD (2000) Correlation between elevated levels of amyloid
beta-peptide in the brain and cognitive decline. JAMA 283:1571–1577
10. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole
GM, Small GW, Huang SC, Barrio JR (2001) Binding characteristics of
radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as
positron emission tomography imaging probes for beta-amyloid plaques
in Alzheimer’s disease. J Neurosci 21:RC189
11. Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst
AD, Scheltens P, Lammertsma AA, van Berckel BN (2009) Differential
association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.
Neurology 73:2079–2085. doi:10.1212/WNL.0b013e3181c679cc
12. Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, Shipley NJ,
Libri V, Lockhart A (2009) Interaction of the amyloid imaging tracer FDDNP
with hallmark Alzheimer’s disease pathologies. J Neurochem 109:623–630.
doi:10.1111/j.1471-4159.2009.05996.x
13. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y (2014) Tau
PET imaging in Alzheimer’s disease. Curr Neurol Neurosci Rep 14:500.
doi:10.1007/s11910-014-0500-6
14. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR,
Lerner AJ, Su MY, Elizarov A et al (2014) Early clinical PET imaging results
with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38:171–184.
doi:10.3233/JAD-130098
15. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Hiraoka K,
Watanuki S, Shidahara M, Miyake M et al (2015) [(18)F]THK-5117 PET for
assessing neurofibrillary pathology in Alzheimer’s disease. Eur J Nucl Med
Mol Imaging 42:1052–1061. doi:10.1007/s00259-015-3035-4
16. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR,
Trojanowski JQ, Lee VM, Ono M et al (2013) Imaging of tau pathology in a
tauopathy mouse model and in Alzheimer patients compared to normal
controls. Neuron 79:1094–1108. doi:10.1016/j.neuron.2013.07.037
17. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti
M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T et al (2013) Novel
18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in
Alzheimer disease. J Nucl Med 54:1420–1427. doi:10.2967/jnumed.112.117341
18. Gillberg PG, Jossan SS, Askmark H, Aquilonius SM (1986) Large-section cryomicrot-
omy for in vitro receptor autoradiography. J Pharmacol Methods 15:169–180
19. Duvernoy HM (2005) The Human Hippocampus. Springer, City
20. Okamura N, Suemoto T, Shimadzu H, Suzuki M, Shiomitsu T, Akatsu H,
Yamamoto T, Staufenbiel M, Yanai K, Arai H et al (2004) Styrylbenzoxazole
derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci
24:2535–2541. doi:10.1523/JNEUROSCI.4456-03.2004
21. Shin J, Kepe V, Barrio JR, Small GW (2011) The merits of FDDNP-PET imaging
in Alzheimer’s disease. Journal of Alzheimer’s disease: JAD 26(Suppl 3):135–145.
doi:10.3233/JAD-2011-0008
22. Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G (2008) Amyloid and
tau imaging, neuronal losses and function in mild cognitive impairment.
J Nutr Health Aging 12:61S–65S
23. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read
S, Satyamurthy N, Petric A, Huang SC et al (2002) Localization of neurofibrillary
tangles and beta-amyloid plaques in the brains of living patients with
Alzheimer disease. Am J Geriatr Psychiatry 10:24–35
24. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M,
Yoshikawa T, Arai H, Iwata R, Kudo Y et al (2013) Comparison of the binding
characteristics of [18F]THK-523 and other amyloid imaging tracers to
Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging 40:125–132.
doi:10.1007/s00259-012-2261-2
25. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol 82:239–259
26. Shinohara M, Fujioka S, Murray ME, Wojtas A, Baker M, Rovelet-Lecrux A, Rademakers
R, Das P, Parisi JE, Graff-Radford NR et al (2014) Regional distribution of synaptic
markers and APP correlate with distinct clinicopathological features in sporadic and
familial Alzheimer’s disease. Brain 137:1533–1549. doi:10.1093/brain/awu046
27. Braak H, Braak E (1990) Alzheimer’s disease: striatal amyloid deposits and
neurofibrillary changes. J Neuropathol Exp Neurol 49:215–224
Lemoine et al. Acta Neuropathologica Communications  (2015) 3:40 Page 11 of 11
